Project Grant R43DK111335

Federal Project Grant Award Summary United Biotherapeutics LLC received a $307,508 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on September 11, 2025, with completion targeted for August 31, 2026. The company is developing a novel therapeutic technology to engineer brown-like adipocytes (referred to as HUMBLE cells) from white preadipocytes...

Federal Grant Award Summary SNC Therapeutics, Inc. received a $700,000 project grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on July 25, 2025, with completion targeted for July 24, 2026. The project, titled "Tolerogenic Nanotherapy to Delay Type 1 Diabetes," focuses on the development and validation of rapamycin-loaded polymersomes...

Federal Grant Award Summary The University of Texas at San Antonio received a $221,252 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 12, 2025, with completion targeted for August 31, 2026. This research initiative will develop a novel drug delivery system designed to modulate adipose tissue function and address obesity-related metabolic...

Federal Grant Award Summary Award Details: Funding Agency: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Federal Grant Program: Diabetes, Digestive, and Kidney Diseases Extramural Research (CFDA 93.847) Awardee: Zvelt Therapeutics Inc. (Ohio) Total Obligation: $974,604.00 Award Date: September 9, 2025 Completion Date: July 31, 2028 Project Description: Zvelt Therapeutics is developing REC2-LEPTIN/DUAL CASSETTE, a recombinant adeno-associated virus (rAAV)-based leptin...

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...

Federal Project Grant Award Summary Velum Inc. received a $315,342 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025, through August 31, 2026. The award funds Phase I development of a novel peptide-based weight loss drug centered on Peptide YY (PYY) triagonist technology. The primary deliverable is the transformation of a...

Federal Grant Award Summary Aavogen Inc. received a $350,000 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 5, 2025, with a completion date of September 4, 2026. The award supports preclinical validation of AVGN7 (rAAV6:SMAD7), a gene therapeutic designed to treat obesity and Type 2 Diabetes Mellitus (T2DM). The primary deliverables include...

Orion Therapeutics Inc. received a $1.25M Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective September 15, 2025, through August 31, 2027. The award supports development of a multifunctional lipid nanoparticle (LNP) delivery platform technology for targeted RNA therapeutics. The core innovation involves customizable lipid nanoparticles incorporating ligands to direct therapeutic nucleic acid payloads to...

Nanosur LLC, a minority-owned biotechnology company, received a $649,999 project grant from the United States Department of Agriculture (USDA) National Institute of Food and Agriculture's (NIFA) Small Business Innovation Research (SBIR) / Small Business Technology Transfer (STTR) Program to develop RNA interference (RNAi)-based insecticides for controlling invasive insect pests in agriculture and forests. The grant, awarded on September 1, 2023, supports Nanosur's work to create selective,...

This Project Grant award from the National Science Foundation (NSF), under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), provides $275,000 to Mellicell Inc. to develop an industrial-scale technology for drug development using mature human fat cells. The broader impact of this SBIR Phase I project is to enable the discovery and development of next-generation therapeutics for obesity and associated medical conditions that can be treated through weight loss. The award will...